cannabis Archives -

CDP Pharma Phorum banner (1422 × 800 px)

Unlock the Pharmaceutical Potential of Cannabinoids

5th International Cannabinoid-Derived Pharmaceuticals Summit

https://pharmaphorum.com/events/5th-international-cannabinoid-derived-pharmaceuticals-summit/

Market Access/ News

Jazz lifted by third EU approval for GW Pharma’s Epidyolex

Phil Taylor cannabis, Epidyolex, epilepsy, EU, GW Pharma, Jazz Pharmaceuticals, rare disease 0 Comment

GW Pharmaceuticals’ Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for

Jazz lifted by third EU approval for GW Pharma’s Epidyolex

https://pharmaphorum.com/news/jazz-lifted-by-third-eu-approval-for-gw-pharmas-epidyolex/

News/ News/ Sales and Marketing

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

Phil Taylor cannabis, Epidiolex, GW Pharma, Jazz Pharmaceuticals, M&A 0 Comment

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

https://pharmaphorum.com/news/jazz-agrees-7-2bn-deal-to-buy-cannabis-meds-pathfinder-gw-pharma/

Market Access/ News/ News

NICE backs NHS funding for two cannabis-based drugs for first time

Richard Staines Bayer, cannabis, GW Pharmaceuticals, market access, multiple sclerosis, NICE 0 Comment

NICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant

NICE backs NHS funding for two cannabis-based drugs for first time

https://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/

R&D/ Views & Analysis/ Views and analysis

De-busting the myths about medical cannabis

mike.hammerton@pharmaphorum.com cannabis, CBD, medical cannabis 0 Comment

Medical cannabis has quickly become the most socially disruptive phenomenon of the new millennium, and it is showing

De-busting the myths about medical cannabis

https://pharmaphorum.com/r-d/views-analysis-r-d/de-busting-the-myths-about-medical-cannabis/

Market Access/ Views & Analysis/ Views and analysis

Addressing the medical cannabis knowledge gap

mike.hammerton@pharmaphorum.com cannabis, CBD, medical cannabis 0 Comment

The legalisation of medical cannabis in November 2018 was hailed as a landmark victory for the British medical

Addressing the medical cannabis knowledge gap

https://pharmaphorum.com/views-analysis-market-access/addressing-the-medical-cannabis-knowledge-gap/

News/ News/ R&D

Sandoz joins medical cannabis drive with Tilray deal

Phil Taylor cannabis, Novartis, Sandoz, Tilray 0 Comment

Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a

Sandoz joins medical cannabis drive with Tilray deal

https://pharmaphorum.com/news/sandoz-joins-medical-cannabis-drive-with-tilray-deal/

News/ News/ R&D

Beckley Canopy Therapeutics raises £7.4m for cannabis R&D

George Underwood addiction, cannabis, opioid, pain 0 Comment

Oxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the

Beckley Canopy Therapeutics raises £7.4m for cannabis R&D

https://pharmaphorum.com/news/beckley-canopy-therapeutics-raises-7-4m-for-cannabis-rd/

Market Access/ News/ News

UK opens doors to cannabis-based therapies via NHS

Joy Persaud cannabis, market access, medical cannabis, NHS 0 Comment

Medical cannabis is available to certain patients across the UK for the first time from today. The groundbreaking

UK opens doors to cannabis-based therapies via NHS

https://pharmaphorum.com/news/medicinal-cannabis-legal-nhs/

Trending

cannabis

Login